Absci (ABSI) Current Deferred Revenue (2020 - 2026)
Absci (ABSI) posted Current Deferred Revenue of $1.0 million for Q1 2026, up 35.32% sequentially from $739000.0 in Q4 2025, and down 9.09% YoY from $1.1 million in Q1 2025.
Absci (ABSI) Current Deferred Revenue (2020 - 2026) Analysis & Trends
Absci has reported Current Deferred Revenue for 7 years, with the latest figure at $1.0 million in Q1 2026.
- Quarterly Current Deferred Revenue fell 9.09% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 million (down 9.09% YoY) and the FY2025 annual result came in at $739000.0, down 32.82% from the prior year.
- Current Deferred Revenue improved to $1.0 million in Q1 2026 per ABSI's latest filing, from $739000.0 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $4.1 million in Q4 2023 and troughed at $345000.0 in Q3 2023.
- A 5-year average of $1.5 million and a median of $1.1 million in 2024 frame the typical range for Current Deferred Revenue.
- The widest YoY moves for Current Deferred Revenue: up 821.35% in 2023, down 87.14% in 2023.
- Over 5 years, Current Deferred Revenue stood at $445000.0 in 2022, then soared by 821.35% to $4.1 million in 2023, then sank by 73.17% to $1.1 million in 2024, then slumped by 32.82% to $739000.0 in 2025, then surged by 35.32% to $1.0 million in 2026.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $1.0 million, $739000.0, and $1.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Absci | 1.58 Bn | 1.37 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.40 Mn |
| Mar 31, 2026 | 1.00 Mn |
| Dec 31, 2025 | 739,000.00 |
| Sep 30, 2025 | 1.60 Mn |
| Jun 30, 2025 | 954,000.00 |
| Mar 31, 2025 | 1.10 Mn |
| Dec 31, 2024 | 1.10 Mn |
| Sep 30, 2024 | 1.80 Mn |
| Jun 30, 2024 | 1.97 Mn |
| Mar 31, 2024 | 3.20 Mn |
| Dec 31, 2023 | 4.10 Mn |
| Sep 30, 2023 | 345,000.00 |
| Jun 30, 2023 | 500,000.00 |
| Mar 31, 2023 | 359,000.00 |
| Dec 31, 2022 | 445,000.00 |
| Sep 30, 2022 | 679,000.00 |
| Jun 30, 2022 | 2.80 Mn |
| Mar 31, 2022 | 2.79 Mn |
| Dec 31, 2021 | 1.40 Mn |
| Sep 30, 2021 | 1.97 Mn |